This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia.
The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of March 26, 2026. It enables VA facilities across multiple Integrated Service Networks to efficiently procure Jynarque for delivery to veterans. Task orders issued under this BPA typically range from $10,000 to $113,000 and support the VA's mission of providing specialized pharmaceutical treatments to veterans nationwide. Otsuka also holds a $396 million Federal Supply Schedule contract with the VA for pharmaceuticals and hematology-related products, further demonstrating its established capability to supply federal healthcare systems.
Generated 3/30/25, 12:48 AM